Renaissance Technologies LLC grew its stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 149.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,600 shares of the company's stock after acquiring an additional 26,700 shares during the quarter. Renaissance Technologies LLC owned about 0.15% of Aerovate Therapeutics worth $118,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. ADAR1 Capital Management LLC increased its stake in shares of Aerovate Therapeutics by 720.7% in the fourth quarter. ADAR1 Capital Management LLC now owns 928,016 shares of the company's stock worth $2,459,000 after acquiring an additional 814,941 shares during the period. Deltec Asset Management LLC purchased a new stake in shares of Aerovate Therapeutics in the fourth quarter worth about $514,000. FNY Investment Advisers LLC acquired a new stake in Aerovate Therapeutics during the fourth quarter worth about $198,000. JPMorgan Chase & Co. raised its position in Aerovate Therapeutics by 1,021.1% during the fourth quarter. JPMorgan Chase & Co. now owns 67,165 shares of the company's stock valued at $178,000 after acquiring an additional 61,174 shares in the last quarter. Finally, Bank of Montreal Can lifted its holdings in Aerovate Therapeutics by 86.8% in the fourth quarter. Bank of Montreal Can now owns 59,097 shares of the company's stock valued at $157,000 after acquiring an additional 27,453 shares during the period.
Aerovate Therapeutics Stock Down 3.9 %
Shares of AVTE stock traded down $0.35 during mid-day trading on Friday, hitting $8.65. 63,694 shares of the stock were exchanged, compared to its average volume of 18,165. Aerovate Therapeutics, Inc. has a 52-week low of $43.75 and a 52-week high of $884.98. The firm has a fifty day moving average of $75.40 and a 200 day moving average of $84.41. The company has a market cap of $250.72 million, a PE ratio of -2.89 and a beta of 0.95.
Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last released its earnings results on Friday, April 25th. The company reported ($3.15) earnings per share for the quarter, topping analysts' consensus estimates of ($10.50) by $7.35. Equities analysts predict that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current year.
Aerovate Therapeutics Announces Dividend
The business also recently announced a dividend, which was paid on Monday, April 28th. Investors of record on Friday, April 25th were given a $84.00 dividend. The ex-dividend date of this dividend was Tuesday, April 29th.
About Aerovate Therapeutics
(
Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
See Also
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
